Comparative Pharmacology
Head-to-head clinical analysis: ACTIDIL versus BROMPHENIRAMINE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTIDIL versus BROMPHENIRAMINE MALEATE.
ACTIDIL vs BROMPHENIRAMINE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
H1-receptor antagonist; competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, blocking histamine-induced bronchoconstriction, vasodilation, and increased capillary permeability.
Competitive antagonist of histamine at H1 receptor sites, suppressing histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction.
2.5 mg orally every 4 to 6 hours as needed; maximum 10 mg per day.
4 mg orally every 4-6 hours, not to exceed 24 mg/day. Alternatively, extended-release: 12 mg every 12 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 20-25 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment.
Terminal half-life 22-25 hours; prolonged in hepatic impairment or elderly (up to 40 hours).
Renal excretion of unchanged drug and metabolites accounts for approximately 60-80% of the administered dose; biliary/fecal elimination comprises the remainder (20-40%).
Renal (85-90% as metabolites, 5-10% unchanged); biliary/fecal <5%.
Category C
Category C
Antihistamine
Antihistamine